{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:47:14Z","timestamp":1761824834451,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.advms.2020.11.003","type":"journal-article","created":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T12:53:27Z","timestamp":1606222407000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["High immunoproteasome concentration in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of longer OS"],"prefix":"10.1016","volume":"66","author":[{"given":"Wioletta","family":"Breczko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Lemancewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"Dzi\u0119cio\u0142","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janusz","family":"K\u0142oczko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Bo\u0142kun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.advms.2020.11.003_bib1","first-page":"24","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment","author":"Moreau","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.advms.2020.11.003_bib2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.advms.2020.11.003_bib3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1515\/hsz-2011-0285","article-title":"Saeki Y the proteasome: molecular machinery and pathophysiological roles","volume":"393","author":"Tanaka","year":"2012","journal-title":"Biol Chem"},{"key":"10.1016\/j.advms.2020.11.003_bib4","doi-asserted-by":"crossref","first-page":"541984","DOI":"10.1155\/2015\/541984","article-title":"New insights into the function of the immunoproteasome in immune and nonimmune cells","volume":"2015","author":"Kimura","year":"2015","journal-title":"Journal of Immunology Research"},{"issue":"11","key":"10.1016\/j.advms.2020.11.003_bib5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1373\/clinchem.2006.072496","article-title":"Circulating proteasomes are functional and have a subtype pattern distinct from 20S proteasomes in major blood cells","volume":"52","author":"Zoeger","year":"2006","journal-title":"Clin Chem"},{"issue":"19","key":"10.1016\/j.advms.2020.11.003_bib6","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","article-title":"Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors","volume":"113","author":"Kuhn","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.advms.2020.11.003_bib7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.seminhematol.2012.04.003","article-title":"The immunoproteasome as a target in hematologic malignancies","volume":"49","author":"Kuhn","year":"2012","journal-title":"Semin Hematol"},{"key":"10.1016\/j.advms.2020.11.003_bib8","doi-asserted-by":"crossref","first-page":"11653","DOI":"10.1523\/JNEUROSCI.23-37-11653.2003","article-title":"Neuronal induction of the immunoproteasome in Huntington\u2019s disease","volume":"23","author":"Diaz-Hernandez","year":"2003","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.advms.2020.11.003_bib9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neurobiolaging.2004.12.004","article-title":"Immunoproteasome and LMP2 polymorphism in aged and Alzhimer\u2019s disease brains","volume":"27","author":"Mishto","year":"2006","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.advms.2020.11.003_bib10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/art.21782","article-title":"Tissue-specific up-regulation of the proteasome subunit beta5i (LMP7) in Sjogren\u2019s syndrome","volume":"54","author":"Egger","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.advms.2020.11.003_bib11","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.febslet.2007.01.061","article-title":"Transformation of the proteasome with age-related macular degeneration","volume":"581","author":"Ethen","year":"2007","journal-title":"FEBS (Fed Eur Biochem Soc) Lett"},{"key":"10.1016\/j.advms.2020.11.003_bib12","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","article-title":"Effects of PS-341 on activity and composition of proteasomes in multiple myeloma cells","volume":"65","author":"Altun","year":"2005","journal-title":"Canc Res"},{"issue":"12","key":"10.1016\/j.advms.2020.11.003_bib13","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3324\/haematol.2013.092411","article-title":"Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors","volume":"98","author":"Niewerth","year":"2013","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.advms.2020.11.003_bib14","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1182\/blood-2009-09-243402","article-title":"Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstr\u00f6m macroglobulinemia","volume":"115","author":"Roccaro","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.advms.2020.11.003_bib15","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.biocel.2006.04.011","article-title":"Immuno-proteasome subunit LMP7 is up-regulated in the ischemic kidney in an experimental model of renovascular hypertension","volume":"38","author":"Ostrowska","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.advms.2020.11.003_bib16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1006\/bbrc.2000.3676","article-title":"Tissue distribution of constitutive proteasomes, immunoproteasomes and PA28 in rats","volume":"277","author":"Noda","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.advms.2020.11.003_bib17","doi-asserted-by":"crossref","first-page":"15883","DOI":"10.1038\/srep15883","article-title":"Immunoproteasome subunit LMP7 deficiency improves obesity and metabolic disorders","volume":"5","author":"Kimura","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.advms.2020.11.003_bib18","doi-asserted-by":"crossref","first-page":"6859","DOI":"10.4049\/jimmunol.167.12.6859","article-title":"Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune responses in the liver","volume":"167","author":"Khan","year":"2001","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.advms.2020.11.003_bib19","doi-asserted-by":"crossref","first-page":"34019","DOI":"10.1038\/srep34019","article-title":"Expression of immunoproteasome genes is regulated by cell intrinsic and extrinsic factors in human cancers","volume":"6","author":"Rouette","year":"2016","journal-title":"Sci Rep"},{"issue":"327","key":"10.1016\/j.advms.2020.11.003_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1126\/scitranslmed.aad6352","article-title":"The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis","volume":"8","author":"Mlecnik","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.advms.2020.11.003_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.yjmcc.2010.02.007","article-title":"Evidence for a role of immunoproteasomes in regulating cardiac muscle mass in diabetic mice","volume":"49","author":"Zu","year":"2010","journal-title":"J\u00a0Mol Cell Cardiol"},{"issue":"3","key":"10.1016\/j.advms.2020.11.003_bib22","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.4049\/jimmunol.1400871","article-title":"Immunoproteasomes shape the transcriptome and regulate the function of dendritic cells","volume":"193","author":"De Verteuil","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"31","key":"10.1016\/j.advms.2020.11.003_bib23","doi-asserted-by":"crossref","first-page":"50873","DOI":"10.18632\/oncotarget.15141","article-title":"Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice","volume":"8","author":"Koerner","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.advms.2020.11.003_bib24","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1021\/acs.jmedchem.9b01226","article-title":"The immunoproteasome: an emerging target in cancer and autoimmune and neurological disorders","volume":"63","author":"Zerfas","year":"2020","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.advms.2020.11.003_bib25","first-page":"215","article-title":"Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance","volume":"121","author":"Wada","year":"1993","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.advms.2020.11.003_bib26","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.bbadis.2008.06.005","article-title":"Extracellular, circulating proteasomes and ubiquitin- incidence and relevance","volume":"1782","author":"Sixt","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.advms.2020.11.003_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1152\/physrev.00027.2001","article-title":"The ubiquitin\u2013proteasome proteolytic pathway: destruction for the sake of construction","volume":"82","author":"Glickman","year":"2002","journal-title":"Physiol Rev"},{"key":"10.1016\/j.advms.2020.11.003_bib28","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1002\/1097-0142(20011115)92:10<2493::AID-CNCR1599>3.0.CO;2-F","article-title":"Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies","volume":"92","author":"Lavabre-Bertrand","year":"2001","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.advms.2020.11.003_bib29","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.leukres.2014.05.008","article-title":"Assessment of proteasome concentration and chymotrypsin-like activity in plasma of patients with newly diagnosed multiple myeloma","volume":"38","author":"Oldziej","year":"2014","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.advms.2020.11.003_bib30","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.23301","article-title":"Enzymatic activity of circulating proteasome correlates with clinical behavior in patients with chronic lymphocytic leukemia","volume":"112","author":"Ma","year":"2008","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.advms.2020.11.003_bib31","first-page":"18","article-title":"The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients","author":"Lemancewicz","year":"2012","journal-title":"Med Sci Mon Int Med J Exp Clin Res"},{"issue":"11","key":"10.1016\/j.advms.2020.11.003_bib32","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-08-3034","article-title":"Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome","volume":"15","author":"Ma","year":"2009","journal-title":"Clin Canc Res"},{"issue":"1","key":"10.1016\/j.advms.2020.11.003_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcp.2014.02.005","article-title":"Anti-Leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924","volume":"89","author":"Niewerth","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.advms.2020.11.003_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2141.2010.08491.x","article-title":"PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo","volume":"152","author":"Singh","year":"2011","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.advms.2020.11.003_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4143\/crt.2017.500","article-title":"Expression of immunoproteasome subunit LMP7 in breast cancer and its association with immune-related markers","volume":"51","author":"Lee","year":"2019","journal-title":"Cancer Res Treat"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112620300432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112620300432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:43:00Z","timestamp":1761824580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112620300432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1896112620300432"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2020.11.003","relation":{},"ISSN":["1896-1126"],"issn-type":[{"type":"print","value":"1896-1126"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High immunoproteasome concentration in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of longer OS","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2020.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}